Nov 16, 2026
  • Cosentyx® (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial1  
  • Approval marks 11th US indication for Cosentyx, building on its decade-long established efficacy and safety profile across immune-mediated diseases1 
  • Cosentyx PMR indication already approved in EU; additional regulatory reviews ongoing, including in Japan

East Hanover, November 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) approved Cosentyx® (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.1 Cosentyx is the first and only anti-interleukin-17 (anti-IL-17) biologic approved for people living with PMR, a common inflammatory disease that primarily affects adults over 50, providing a new treatment option beyond long-term steroid use—the current standard of care, which may be associated with significant side effects and risks.1-5 

“The FDA approval of secukinumab in PMR marks a significant advancement for patients and physicians. Patients with PMR are at increased risk of poor outcomes related to steroids, and the prospect of months or years of additional steroids is disheartening,” said Prof. John Stone, MD, MPH, Professor of Medicine, Harvard Medical School, Massachusetts General Hospital, and global principal investigator for the REPLENISH trial. “For too long, treatment options beyond glucocorticoids have been limited. In the Phase III REPLENISH trial, secukinumab doubled the likelihood of sustained remission while helping patients taper off steroids, which should be the goal of PMR treatment.” 

In the United States, there are approximately 966,000 people living with PMR—a disease characterized by acute pain and stiffness in the shoulders, neck, and hips.2,6 PMR is commonly treated with steroids, but relapses are frequent, affecting up to 40% of patients in the first year.4 Long-term steroid use increases the risk of osteoporosis, cardiovascular disease, and diabetes.3 The approval of Cosentyx as the first anti-IL-17 biologic indicated for people with PMR offers rheumatologists an alternative to long-term steroid use based on more than a decade of clinical experience across immune-mediated diseases.1  

“PMR can make remarkably ordinary things hard: getting out of bed, getting dressed, lifting your arms, getting through the day. For years, patients have had too few treatment options,” said Seth Ginsberg, Co-Founder and President, Global Healthy Living Foundation and CreakyJoints. “The approval of secukinumab offers patients and their clinicians a new therapeutic option and the opportunity for more individualized care.”  

“For more than a decade, Cosentyx has helped redefine what’s possible for people living with immune-mediated diseases, delivering meaningful outcomes across multiple conditions,” said Victor Bultó, President, US, Novartis. “With this approval in PMR, our 11th US indication for Cosentyx, we are expanding those benefits to a community that has had limited treatment options for far too long. This milestone reflects our commitment to continually investigate where our medicines can help patients most, extending the impact of proven innovations to new areas of significant unmet need.” 

About Cosentyx 
Cosentyx is a fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation underlying multiple immune-mediated inflammatory diseases. It is approved worldwide for use in adults with psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), hidradenitis suppurativa (HS), and polymyalgia rheumatica (PMR).1,7-9 Cosentyx is also approved for use in pediatric patients, including those with PsO, juvenile idiopathic arthritis subtypes such as juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA), and in the U.S. for pediatric patients aged 12 years and older with moderate to severe HS and for juvenile AS.1,10,11  

About the REPLENISH trial
This latest FDA approval is based on results from the pivotal Phase III REPLENISH trial (NCT05767034), a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted across 27 countries, evaluating the efficacy and safety of Cosentyx in patients with polymyalgia rheumatica (PMR).12

Patients were randomized into three treatment arms: Cosentyx 300mg, Cosentyx 150mg, or placebo, all in combination with a 24-week steroid taper regimen.12 The data were published in the New England Journal of Medicine and simultaneously presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress on June 3, 2026.13,14

  • The primary endpoint was met, with adults with PMR treated with Cosentyx 150 mg achieving sustained remission at twice the rate of those on placebo (40.5% vs 20.5%) at Week 52, following a 24-week steroid tapering.1,13
  • Key secondary endpoints included the proportion of patients achieving complete sustained remission at week 52, the adjusted annual cumulative steroid dose, and the time to first use of escape or rescue treatment through week 52.13
  • Safety profile in PMR trial remained consistent with the established Cosentyx profile.1,13
  • Serious adverse events occurred in 15.9% of the patients in the Cosentyx 150 mg group and in 14.2% of those in the placebo group.13
  • Patients on Cosentyx 150 mg experienced an increased proportion of hypersensitivity reactions (including eczema, dermatitis, rash and urticaria) and urinary tract infections (UTI) vs. placebo (14% vs. 9%, and 13% vs. 7%, respectively). One patient in the Cosentyx 150 mg group experienced a serious event of UTI, and a fatal case of cryptococcal meningitis occurred in a patient treated with Cosentyx.1,13

Novartis also filed these data for regulatory review in Japan, in addition to other countries.

About polymyalgia rheumatica (PMR) 
Polymyalgia rheumatica (PMR) is a common inflammatory disease in adults aged 50 years and older, typically characterized by acute pain and stiffness in the shoulders, neck, and hips.2 Relapses are frequent, affecting up to 40% of patients in the first year. Long-term steroid use is the current standard of care and carries significant risks, including osteoporosis and diabetes.3,4 Beyond physical complications, PMR substantially impairs quality of life through pain, fatigue, restricted mobility, and fear of relapse.2,15,16 

About Novartis Immunology 
At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with complex and often overlooked autoimmune and other immune-mediated diseases, so they can reclaim their lives. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology. 

INDICATIONS
COSENTYX® (secukinumab) is a prescription medicine used to treat:

  • adults and children 6 years of age and older with moderate to severe plaque psoriasis (PsO) that involves large areas or many areas of the body, and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light alone or with systemic therapy)
  • adults and children 2 years of age and older with active psoriatic arthritis (PsA)
  • adults and children 12 years of age and older with active ankylosing spondylitis (AS)
  • adults with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation
  • children 4 years of age and older with active enthesitis-related arthritis (ERA)
  • adults and children 12 years of age and older with moderate to severe hidradenitis suppurativa (HS)
  • adults with polymyalgia rheumatica (PMR) after corticosteroids have been used and did not work well or when a slow decrease in the dose of corticosteroids (taper) cannot be tolerated

IMPORTANT SAFETY INFORMATION
Do not use COSENTYX if you have had a severe allergic reaction to secukinumab or any of the other ingredients in COSENTYX. See the Medication Guide for a complete list of ingredients.

What is the most important information I should know about COSENTYX?

COSENTYX is a medicine that affects your immune system. COSENTYX may increase your risk of having serious side effects such as:

Infections
COSENTYX may lower the ability of your immune system to fight infections and may increase your risk of infections. Some people have had serious infections while taking COSENTYX, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses. Some people have died from these infections.

  • Your doctor should check you for TB before starting treatment with COSENTYX.
  • If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with COSENTYX and during treatment with COSENTYX.
  • Your doctor should watch you closely for signs and symptoms of TB during treatment with COSENTYX. Do not use COSENTYX if you have an active TB infection.

Before starting COSENTYX, tell your doctor if you:

  • are being treated for an infection
  • have an infection that does not go away or that keeps coming back
  • have TB or have been in close contact with someone with TB
  • have or have had Hepatitis B
  • think you have an infection or have symptoms of an infection such as: fevers, sweats, or chills; muscle aches; cough; shortness of breath; blood in your phlegm; weight loss; warm, red, or painful skin or sores on your body; diarrhea or stomach pain; burning when you urinate or urinate more often than normal.

After starting COSENTYX, call your doctor right away if you have any signs of infection listed above. Do not use COSENTYX if you have any signs of infection unless you are instructed to by your doctor.

What are the possible side effects of COSENTYX?

COSENTYX may cause serious side effects, including:

Serious allergic reactions
Serious allergic reactions can occur. Get emergency medical help right away if you get any of the following symptoms: feeling faint; swelling of your face, eyelids, lips, mouth, tongue, or throat; trouble breathing or throat tightness; chest tightness; skin rash or hives (red, itchy bumps).

If you have a severe allergic reaction, do not give another injection of COSENTYX.

Inflammatory bowel disease
New cases of inflammatory bowel disease or “flare-ups” can happen with COSENTYX and can sometimes be serious. If you have inflammatory bowel disease (ulcerative colitis or Crohn’s disease), tell your doctor if you have worsening disease symptoms during treatment with COSENTYX or develop new symptoms of stomach pain or diarrhea.

Severe skin reactions that look like eczema can happen during treatment with COSENTYX from days to months after your first dose and can sometimes lead to hospitalization. Your doctor may temporarily stop treatment with COSENTYX if you develop severe skin reactions. Tell your doctor if you get any of the following signs or symptoms: redness or rash; itching; small bumps or patches; your skin is dry or feels like leather; blisters on the hands or feet that ooze or become crusty or skin peeling.

The most common side effects of COSENTYX include: cold symptoms, diarrhea, and upper respiratory tract infections.

These are not all of the possible side effects of COSENTYX. Call your doctor for medical advice about side effects.

 Before using COSENTYX, tell your doctor if you:

  • have any of the conditions or symptoms listed above for infections.
  • have inflammatory bowel disease (Crohn’s disease or ulcerative colitis).
  • are allergic to latex. The removable needle cap on the COSENTYX Sensoready® pen and prefilled syringes (150 mg/mL, 75 mg/0.5 mL) contains latex.
  • have recently received or are scheduled to receive an immunization (vaccine). People who take COSENTYX should not receive live vaccines. Children should be brought up to date with all vaccines before starting COSENTYX.
  • have any other medical conditions and all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Keep a list of your medicines to show your healthcare provider and pharmacist when you get a new medicine.
  • are pregnant or plan to become pregnant. It is not known if COSENTYX can harm your unborn baby. You and your doctor should decide if you will use COSENTYX.
  • are breastfeeding or plan to breastfeed. It is not known if COSENTYX passes into your breast milk.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information, including Medication Guide.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at www.novartis.us and connect with us on LinkedIn US, X/Twitter US and Instagram US.

References 

  1. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp. 
  2. Espígol-Frigolé G, et al. Lancet. 2023;402(10411):1459–72. 
  3. Mazzantini M, et al. J Rheumatol. 2012 Mar;39(3):552-7. 
  4. Floris A, et al. Clin Rheumatol. 2022;41(1):19-31 
  5. Kevzara. Prescribing Information. Sanofi and Regeneron Pharmaceuticals, Inc. 
  6. Data on File. 
  7. Novartis Europharm Limited. Cosentyx® (secukinumab): Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf [Last accessed: August 2026]. 
  8. Girolomoni G, Mrowietz U and Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167:717-724. 
  9. Novartis Cosentyx shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials [Last accessed: August 2026]. 
  10. Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis [Last accessed: August 2026]. 
  11. Novartis Cosentyx receives positive CHMP opinion for expanded use in childhood arthritic conditions. [Press release]. Available at: https://www.novartis.com/news/media-releases/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-conditions [Last accessed: August 2026]. 
  12. ClinicalTrials.gov. NCT05767034. [Last accessed: August 2026]. 
  13. Stone JH, Buttgereit F, Saraux A, et al. Secukinumab in polymyalgia rheumatica. New England Journal of Medicine. 2026. doi:10.1056/NEJMoa2602567. https://www.nejm.org/doi/full/10.1056/NEJMoa2602567. 
  14. Dejaco C, et al. Secukinumab in polymyalgia rheumatica: Results of the phase 3 REPLENISH trial. Oral Presentation #OP0116. Presented at: European Congress of Rheumatology (EULAR) 2026; June 3-6, 2026; London, UK. 
  15. Hutchings A, et al. Arthritis Rheum. 2007;57(5):803–9 
  16. Twohig H, et al. Patient Educ Couns. 2015;98(5):645–50. 

Novartis Media Relations
E-mail: [email protected]

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]